Copyright
©The Author(s) 2019.
World J Gastroenterol. Jun 7, 2019; 25(21): 2665-2674
Published online Jun 7, 2019. doi: 10.3748/wjg.v25.i21.2665
Published online Jun 7, 2019. doi: 10.3748/wjg.v25.i21.2665
n = 33 | |
Age (yr), median (P25-P75) | 64 (59-73) |
Males, n (%) | 18 (54.5) |
BMI > 25 kg/m2, n (%) | 26 (78.8) |
ALT (UI/L), median (P25-P75) | 21 (18-26) |
Platelets (× 103/μL), median (P25-P75) | 77 (58-100) |
Total bilirubin (mg/dL), median (P25-P75) | 1.1 (0.8-1.6) |
Albumin (g/dL), median (P25-P75) | 3.9 (3.8-4.1) |
Baseline Child-Pugh A/B/C, n (%) | 25 (75.8)/8 (24.2)/0 |
HVPG Child-Pugh A/B/C, n (%) | 30 (90.9)/3 (9.1)/0 |
Baseline MELD score, median (P25-P75) | 10 (9-11) |
HVPG MELD score, median (P25-P75) | 9 (8-12) |
Baseline TE (kPa), median (P25-P75) | 24.8 (17.3-34.3) |
HVPG TE (kPa), median (P25-P75) | 21.7 (16.6-26.8) |
Baseline ascites, n (%) | 12 (36.4) |
HVPG ascites, n (%) | 3 (9.1) |
Propranolol/Carvedilol, n (%) | 14 (46.7)/16 (53.3) |
Primary prophylaxis indication, n (%) | 29 (88) |
Large oesophageal varices | 26 (79) |
Small oesophageal varices + Child-Pugh B | 3 (9) |
Secondary prophylaxis, n (%) | 4 (12) |
- Citation: Abadía M, Montes ML, Ponce D, Froilán C, Romero M, Poza J, Hernández T, Fernández-Martos R, Olveira A, on behalf of the “La Paz Portal Hypertension” Study Group Investigators. Management of betablocked patients after sustained virological response in hepatitis C cirrhosis. World J Gastroenterol 2019; 25(21): 2665-2674
- URL: https://www.wjgnet.com/1007-9327/full/v25/i21/2665.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i21.2665